Stock Update (NASDAQ:AMGN): Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies

[PR Newswire] – THOUSAND OAKS, Calif., Nov. 23, 2015 /PRNewswire/ — Amgen (AMGN) today announced that CVS Health will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. “Ensuring access to . . . → Read More: Stock Update (NASDAQ:AMGN): Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies Similar Articles: Market Update (NASDAQ:AMGN): UK cost watchdog turns down Amgen’s new cholesterol drug Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Present New Long-Term Repatha™ (Evolocumab) Data Analysis At ESC Congress 2015 Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Repatha effective; question is for which patients–FDA